Association between BKPyV Serotype i Antibody Level and Natalizumab-Associated Progressive Multifocal Leukoencephalopathy

Francesca Rossi, Luca Prosperini, Nicola De Rossi, Ruggero Capra, Daniela Rivanera, Xiuhong Li, Paola Cinque, Laura Passeri, Carlo Pozzilli, Raphael P Viscidi

Research output: Contribution to journalArticle

Abstract

To determine the association between BK polyomavirus (BKPyV) types 1 and 4 capsid antibody and natalizumab-associated progressive multifocal leukoencephalopathy (PML) in patients with multiple sclerosis (MS), serum samples were obtained from 10 natalizumab-associated PML cases and 130 control MS patients treated with natalizumab, and 82 control MS patients never exposed to natalizumab. In a sex- and age-adjusted regression model, BKPyV serotype 1 antibody levels were significantly higher in natalizumab-treated controls (p = 0.009) compared with cases, and were higher in controls never treated with natalizumab compared with cases, but the difference did not reach statistical significance (p = 0.158). There was no association between BKPyV serotype 4 antibody and PML. We hypothesize that a robust immune response to BKPyV may be protective against the development of PML.

Original languageEnglish (US)
Pages (from-to)622-626
Number of pages5
JournalViral Immunology
Volume30
Issue number8
DOIs
StatePublished - Oct 1 2017

Fingerprint

BK Virus
Progressive Multifocal Leukoencephalopathy
Antibodies
Multiple Sclerosis
Capsid
Serogroup
Natalizumab
Serum

Keywords

  • BKPyV
  • JCPyV
  • multiple sclerosis
  • natalizumab
  • PML

ASJC Scopus subject areas

  • Immunology
  • Molecular Medicine
  • Virology

Cite this

Association between BKPyV Serotype i Antibody Level and Natalizumab-Associated Progressive Multifocal Leukoencephalopathy. / Rossi, Francesca; Prosperini, Luca; De Rossi, Nicola; Capra, Ruggero; Rivanera, Daniela; Li, Xiuhong; Cinque, Paola; Passeri, Laura; Pozzilli, Carlo; Viscidi, Raphael P.

In: Viral Immunology, Vol. 30, No. 8, 01.10.2017, p. 622-626.

Research output: Contribution to journalArticle

Rossi, F, Prosperini, L, De Rossi, N, Capra, R, Rivanera, D, Li, X, Cinque, P, Passeri, L, Pozzilli, C & Viscidi, RP 2017, 'Association between BKPyV Serotype i Antibody Level and Natalizumab-Associated Progressive Multifocal Leukoencephalopathy', Viral Immunology, vol. 30, no. 8, pp. 622-626. https://doi.org/10.1089/vim.2017.0039
Rossi, Francesca ; Prosperini, Luca ; De Rossi, Nicola ; Capra, Ruggero ; Rivanera, Daniela ; Li, Xiuhong ; Cinque, Paola ; Passeri, Laura ; Pozzilli, Carlo ; Viscidi, Raphael P. / Association between BKPyV Serotype i Antibody Level and Natalizumab-Associated Progressive Multifocal Leukoencephalopathy. In: Viral Immunology. 2017 ; Vol. 30, No. 8. pp. 622-626.
@article{1c790095d68c45278d2b7c70357f6627,
title = "Association between BKPyV Serotype i Antibody Level and Natalizumab-Associated Progressive Multifocal Leukoencephalopathy",
abstract = "To determine the association between BK polyomavirus (BKPyV) types 1 and 4 capsid antibody and natalizumab-associated progressive multifocal leukoencephalopathy (PML) in patients with multiple sclerosis (MS), serum samples were obtained from 10 natalizumab-associated PML cases and 130 control MS patients treated with natalizumab, and 82 control MS patients never exposed to natalizumab. In a sex- and age-adjusted regression model, BKPyV serotype 1 antibody levels were significantly higher in natalizumab-treated controls (p = 0.009) compared with cases, and were higher in controls never treated with natalizumab compared with cases, but the difference did not reach statistical significance (p = 0.158). There was no association between BKPyV serotype 4 antibody and PML. We hypothesize that a robust immune response to BKPyV may be protective against the development of PML.",
keywords = "BKPyV, JCPyV, multiple sclerosis, natalizumab, PML",
author = "Francesca Rossi and Luca Prosperini and {De Rossi}, Nicola and Ruggero Capra and Daniela Rivanera and Xiuhong Li and Paola Cinque and Laura Passeri and Carlo Pozzilli and Viscidi, {Raphael P}",
year = "2017",
month = "10",
day = "1",
doi = "10.1089/vim.2017.0039",
language = "English (US)",
volume = "30",
pages = "622--626",
journal = "Viral Immunology",
issn = "0882-8245",
publisher = "Mary Ann Liebert Inc.",
number = "8",

}

TY - JOUR

T1 - Association between BKPyV Serotype i Antibody Level and Natalizumab-Associated Progressive Multifocal Leukoencephalopathy

AU - Rossi, Francesca

AU - Prosperini, Luca

AU - De Rossi, Nicola

AU - Capra, Ruggero

AU - Rivanera, Daniela

AU - Li, Xiuhong

AU - Cinque, Paola

AU - Passeri, Laura

AU - Pozzilli, Carlo

AU - Viscidi, Raphael P

PY - 2017/10/1

Y1 - 2017/10/1

N2 - To determine the association between BK polyomavirus (BKPyV) types 1 and 4 capsid antibody and natalizumab-associated progressive multifocal leukoencephalopathy (PML) in patients with multiple sclerosis (MS), serum samples were obtained from 10 natalizumab-associated PML cases and 130 control MS patients treated with natalizumab, and 82 control MS patients never exposed to natalizumab. In a sex- and age-adjusted regression model, BKPyV serotype 1 antibody levels were significantly higher in natalizumab-treated controls (p = 0.009) compared with cases, and were higher in controls never treated with natalizumab compared with cases, but the difference did not reach statistical significance (p = 0.158). There was no association between BKPyV serotype 4 antibody and PML. We hypothesize that a robust immune response to BKPyV may be protective against the development of PML.

AB - To determine the association between BK polyomavirus (BKPyV) types 1 and 4 capsid antibody and natalizumab-associated progressive multifocal leukoencephalopathy (PML) in patients with multiple sclerosis (MS), serum samples were obtained from 10 natalizumab-associated PML cases and 130 control MS patients treated with natalizumab, and 82 control MS patients never exposed to natalizumab. In a sex- and age-adjusted regression model, BKPyV serotype 1 antibody levels were significantly higher in natalizumab-treated controls (p = 0.009) compared with cases, and were higher in controls never treated with natalizumab compared with cases, but the difference did not reach statistical significance (p = 0.158). There was no association between BKPyV serotype 4 antibody and PML. We hypothesize that a robust immune response to BKPyV may be protective against the development of PML.

KW - BKPyV

KW - JCPyV

KW - multiple sclerosis

KW - natalizumab

KW - PML

UR - http://www.scopus.com/inward/record.url?scp=85031089186&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85031089186&partnerID=8YFLogxK

U2 - 10.1089/vim.2017.0039

DO - 10.1089/vim.2017.0039

M3 - Article

C2 - 28836899

AN - SCOPUS:85031089186

VL - 30

SP - 622

EP - 626

JO - Viral Immunology

JF - Viral Immunology

SN - 0882-8245

IS - 8

ER -